Search

Displaying results 1621 - 1630 of 8696 in total
  1. Drug

    Xylometazoline

    go.drugbank.com/drugs/DB06694
    Approved

    Xylometazoline is an imidazoline derivative [A228523] with sympathomimetic and nasal decongestant activity.

    Mixtures: nasic pur Nasenspray für Kinder, nasic - Nasenspray für Kinder 5 mg/500 mgCategories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists
  2. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    [L39496] IgG antibodies, including the autoantibodies responsible for MG symptoms, can be 'recycled', a process that significantly extends their half-life by evading lysosomal degradation via binding with … Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis.

    Categories: Neonatal Fc Receptor Blocker
  3. Drug

    Promazine

    go.drugbank.com/drugs/DB00420
    ApprovedVet approvedWithdrawn

    It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  4. Drug

    Thiocolchicoside

    go.drugbank.com/drugs/DB11582
    Investigational

    Thiocolchicoside is a semi-synthetic derivative of the colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of Superba gloriosa. It is a muscle relaxant with anti-inflammatory and analgesic effects. It...

    Mixtures: REUTRID®MAX, PARALGEN MAX
  5. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.

    Mixtures: ARTISS SOLUTIONS FOR SEALANT, DEEP FROZEN
  6. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects[L31718]. … Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who are hospitalized (NCT04535167).

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Target

    Cannabinoid receptor 1

    go.drugbank.com/bio_entities/BE0000061
    TargetHumans

    G protein-coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such … In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type.

    Polypeptides: Cannabinoid receptor 1Function: cannabinoid receptor activity
  8. Target

    Cannabinoid receptor 2

    go.drugbank.com/bio_entities/BE0000095
    TargetHumans

    May function in inflammatory response, nociceptive transmission and bone homeostasis … Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase.

    Polypeptides: Cannabinoid receptor 2Function: cannabinoid receptor activity
  9. Target

    Substance-P receptor

    go.drugbank.com/bio_entities/BE0000384
    TargetHumans

    Substance P binding to its receptor triggers G protein-coupled receptor signaling via activation of phosphatidylinositol hydrolysis by phospholipase C. … The rank order of affinity of this receptor to tachykinins is: substance P > neurokinin A/substance K > neurokinin B/neuromedin-K (PubMed:1718267).

    Polypeptides: Substance-P receptorSynonyms: NK-1 receptor, Tachykinin receptor 1
  10. Target

    Dopamine receptor D4

    go.drugbank.com/bio_entities/BE0000389
    TargetHumans

    G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure (PubMed:16423344 … Dopamine receptors can be classified in two categories: (1) DRD4 (together with DRD2 and DRD3) is a D2-type receptor and is coupled to G(i)/G(o) G proteins, mediating inhibition of adenylate cyclase activity

    Polypeptides: Dopamine receptor D4Synonyms: Dopamine D4 receptor, D(2C) dopamine receptor